Schenk Robyn L, Strasser Andreas, Dewson Grant
Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Melbourne, Victoria 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne, Victoria 3010, Australia.
Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Melbourne, Victoria 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne, Victoria 3010, Australia.
Biochem Biophys Res Commun. 2017 Jan 15;482(3):459-469. doi: 10.1016/j.bbrc.2016.10.100. Epub 2017 Feb 3.
In 1988, the BCL-2 protein was found to promote cancer by limiting cell death rather than enhancing proliferation. This discovery set the wheels in motion for an almost 30 year journey involving many international research teams that has recently culminated in the approval for a drug, ABT-199/venetoclax/Venclexta that targets this protein in the treatment of cancer. This review will describe the long and winding path from the discovery of this protein and understanding the fundamental process of apoptosis that BCL-2 and its numerous homologues control, through to its exploitation as a drug target that is set to have significant benefit for cancer patients.
1988年，人们发现BCL-2蛋白通过限制细胞死亡而非增强增殖来促进癌症。这一发现推动了一个长达近30年的研究进程，许多国际研究团队参与其中，最近这一进程以一种名为ABT-199/维奈托克/维可来的药物获批而告终，该药物在癌症治疗中靶向这种蛋白。这篇综述将描述从发现这种蛋白、理解BCL-2及其众多同源物所控制的细胞凋亡基本过程，到将其开发为一种有望给癌症患者带来显著益处的药物靶点的漫长而曲折的历程。
